Merck's Strategic Shift Signals New Growth Horizons - Merck & Co (NYSE:MRK)

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

Merck creating separate cancer unit to offset looming Keytruda loss

Pharma giant to split its human-health business in two, appoints Jannie Oosthuizen to lead unit

Merck to create separate cancer business as Keytruda patent loss looms

Merck said on ⁠Monday it will split its human-health ​business into ​two ​divisions, separating its cancer franchise from ⁠its non-oncology ‌medicines.

Merck's Strategic Shift Signals New Growth Horizons - Merck & Co (NYSE:MRK)

Merck restructures its Human Health business as Keytruda faces a 2028 patent loss.

Merck to split cancer, specialty drug businesses in leadership shakeup

Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

Merck Restructures Human Health To Highlight Oncology And Post Keytruda Growth

Merck (NYSE:MRK) plans to split its Human Health business into two divisions: one for oncology and one for specialty, pharma, and infectious diseases. The restructuring is tied to the anticipated patent loss of cancer drug Keytruda and is intended to sharpen management focus across franchises. New leadership roles, more than 20 identified growth drivers, and a deep Phase 3 pipeline are central elements of the new setup. For you as an investor, t…